LONDON and CAMBRIDGE, Mass., May 7, 2026
Beacon Therapeutics announced encouraging 12-month safety and efficacy results from its ongoing Phase 2 DAWN clinical trial evaluating laruparetigene zovaparvovec (laru-zova) for the treatment of X-linked retinitis pigmentosa (XLRP), a rare inherited retinal disease that causes progressive vision loss and eventual blindness. The new data, presented during the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting in Denver, Colorado, demonstrated sustained improvements across several key measures of visual function while reinforcing the therapy’s favorable safety profile.
The clinical update strengthens Beacon Therapeutics’ position within the rapidly advancing ophthalmic gene therapy market, where companies are racing to develop transformative treatments for inherited retinal disorders that currently lack approved therapeutic options. Researchers and industry analysts say positive long-term efficacy signals are especially important in gene therapy development because they may indicate durable biological activity capable of slowing or reversing disease progression.
Gene Therapy Shows Sustained Vision Improvements
According to Beacon Therapeutics, patients treated with laru-zova continued to experience meaningful improvements in critical visual function measurements through month 12 of the trial. Investigators reported sustained gains in low luminance visual acuity (LLVA) and mean macular sensitivity measured by microperimetry, both considered important indicators of functional vision performance in patients with retinal degeneration disorders.
The company disclosed that 50% of participants receiving higher-dose treatment achieved at least a two-line visual acuity improvement from baseline, while 25% achieved improvements of at least three lines using ETDRS visual acuity measurements. Additionally, 67% of participants receiving lower-dose therapy achieved at least two-line improvements from baseline. Researchers also observed sustained improvements in microperimetry sensitivity compared with baseline measurements, suggesting the therapy may help preserve retinal function over time.
Advertisement
Beacon Therapeutics stated that laru-zova remained generally well-tolerated throughout the 12-month evaluation period. Most ocular treatment-emergent adverse events were mild to moderate in severity and were primarily linked to surgical procedures or corticosteroid use rather than the gene therapy itself.
Company executives emphasized that the growing body of clinical evidence supports continued development of laru-zova as a potential treatment option for patients suffering from XLRP caused by mutations in the RPGR gene, a major genetic driver of inherited retinal degeneration.
XLRP Represents Major Unmet Medical Need
X-linked retinitis pigmentosa is a severe inherited retinal disease that predominantly affects males and progressively destroys photoreceptor cells in the retina. The condition often begins during childhood and leads to worsening visual dysfunction, night blindness, tunnel vision, and eventual legal blindness. Currently, there are no approved treatments capable of reversing or stopping disease progression in many XLRP patients.
Beacon Therapeutics explained that laru-zova is designed to restore the natural function of retinal rods and cones by delivering a functional copy of the RPGRORF15 gene, enabling production of the full-length protein required for retinal cell function. The therapy has already received several major regulatory recognitions, including Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designation from the U.S. FDA, along with PRIME designation from the European Medicines Agency and Orphan Drug Designation from both U.S. and European regulators.
Beacon Advances Toward Pivotal Phase 2/3 Trial Results
Beacon Therapeutics confirmed that enrollment has been completed in the ongoing VISTA Phase 2/3 pivotal trial, which is evaluating the efficacy, safety, and tolerability of laru-zova compared with untreated control groups. The company expects to report topline data from the VISTA study during the second half of 2026, a milestone that could significantly influence the future development pathway for the therapy.
Industry experts believe positive pivotal data could position laru-zova among the leading next-generation ocular gene therapies targeting inherited blindness disorders. As investment in retinal gene therapy continues accelerating worldwide, successful development programs may help reshape treatment strategies for patients suffering from previously untreatable genetic eye diseases.
Source: Beacon Therapeutics press release
